First Bancorp Inc ME Makes New $500,000 Investment in IDEXX Laboratories, Inc. $IDXX

First Bancorp Inc ME purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 950 shares of the company’s stock, valued at approximately $500,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories during the second quarter valued at about $25,000. SHP Wealth Management bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $26,000. Elevation Wealth Partners LLC grew its stake in shares of IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares during the last quarter. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $26,000. Finally, WealthCollab LLC acquired a new stake in IDEXX Laboratories during the second quarter valued at approximately $30,000. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on IDXX. UBS Group upped their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Barclays dropped their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, Citigroup upped their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $550.01 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98. The business’s 50-day moving average price is $559.34 and its two-hundred day moving average price is $575.26. The company has a market capitalization of $43.33 billion, a P/E ratio of 38.68, a price-to-earnings-growth ratio of 2.99 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the business earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.